Testing for Cancer of the Skin

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
Cancer of the Skin+1 More
Mobile-based and user-centered intervention - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Hypothesis: More than 80% of the participants (n=40) will complete the intervention at three month (intervention completion) and the six month follow-up (retention rate as feasibility). More than 70% of the participants will report high overall study satisfaction (acceptability) with the intervention and study. This pre-pilot will inform intervention and procedural refinements for the pilot. Hypothesis: Participants who receive the intervention (n=57) will report more skin cancer-related preventive behaviors (e.g., mean of summed score of sun protection behaviors such as use of sunscreen, etc.) at three month and six month follow-up compared to those in the control condition (n=57, who will receive general information about physical activity and nutrition).

Eligible Conditions

  • Cancer of the Skin

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Cancer of the Skin

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: The change is being assessed at baseline, three month and six month follow-up intervals

Changes at baseline, three month and six month follow-up intervals
Skin examination by a health care professional
Skin self-examination
The change is being assessed at baseline, three month and six month follow-up intervals
Seek shade behavior by self-report
Sun protection behavior by self-report
Wear protective clothing behavior by self-report
Wear sunglasses behavior by self-report
Wear wide-brimmed hat behavior by self-report

Trial Safety

Safety Progress

1 of 3

Other trials for Cancer of the Skin

Trial Design

4 Treatment Groups

Control group: physical activity and nutrition information
1 of 4
Testing
1 of 4
Mobile skin cancer intervention
1 of 4
Interviews and focus groups
1 of 4
Active Control
Experimental Treatment

210 Total Participants · 4 Treatment Groups

Primary Treatment: Testing · No Placebo Group · N/A

Testing
Behavioral
Experimental Group · 1 Intervention: Mobile-based and user-centered intervention · Intervention Types: Behavioral
Mobile skin cancer intervention
Behavioral
Experimental Group · 1 Intervention: Mobile-based and user-centered intervention · Intervention Types: Behavioral
Interviews and focus groups
Behavioral
Experimental Group · 1 Intervention: Mobile-based and user-centered intervention · Intervention Types: Behavioral
Control group: physical activity and nutrition information
Behavioral
ActiveComparator Group · 1 Intervention: Baseline survey and post-intervention survey. · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: the change is being assessed at baseline, three month and six month follow-up intervals

Trial Background

Zhaomeng Niu, Research Associate
Principal Investigator
Rutgers, The State University of New Jersey
Closest Location: Rutgers Cancer Institute of New Jersey · New Brunswick, NJ
2013First Recorded Clinical Trial
1 TrialsResearching Cancer of the Skin
158 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You must be at least 18 years old.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.